Risk factors
Beam Therapeutics (BEAM) risk factors
Item 1A of every Beam Therapeutics Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors104 risks10 new2 dropped11 reworded
Beam Therapeutics added risks covering debt service and cash flow generation, new FDA Diversity Action Plan requirements under FDORA, and global tariff policies.
Filed Feb 24, 2026 - FY2024 10-K risk factors96 risks
Beam Therapeutics faces significant financial operating losses with an accumulated deficit of $1.6 billion as of December 31, 2024. The company relies heavily on unproven base editing technology and early-stage clinical trials without any commercial revenue. Substantial additional capital will be required to fund research, clinical development, and a 100,000 square foot manufacturing facility.
Filed Feb 25, 2025